1-5 of 5
Michael Lees
Close
Sort by
Journal Articles

Will Rivaroxaban Be Cost-Effective for Prevention of Venous Thromboembolism after Total Hip Replacement in US Patients?

Louis Kwong, Alexander Diamantopoulos, Fiona Forster, Nishan Sengupta, Michael Lees
Journal: Blood
Blood (2008) 112 (11): 1290.
https://doi.org/10.1182/blood.V112.11.1290.1290
Published: 2008
Journal Articles

Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada.

Philip Wells, MD, FRCPC, MSc, Alexander Diamantopoulos, Fiona Forster, Michael Lees, Heather McDonald
Journal: Blood
Blood (2008) 112 (11): 1291.
https://doi.org/10.1182/blood.V112.11.1291.1291
Published: 2008
Journal Articles

Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement.

Alexander Diamantopoulos, Corrine LeReun, Farhat Rasul, Michael Lees, Maria Kubin, Philip Wells, MD, FRCPC, MSc
Journal: Blood
Blood (2008) 112 (11): 1292.
https://doi.org/10.1182/blood.V112.11.1292.1292
Published: 2008
Journal Articles

Rivaroxaban for Prevention of Venous Thromboembolism after Total Knee Replacement: Impact on Healthcare Costs Based on the RECORD4 Study.

Louis Kwong, Nishan Sengupta, Michael Lees
Journal: Blood
Blood (2008) 112 (11): 1289.
https://doi.org/10.1182/blood.V112.11.1289.1289
Published: 2008
Journal Articles

Rivaroxaban for Prevention of Venous Thromboembolism after Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study.

Louis Kwong, MD, Michael Lees, M.COM, Nishan Sengupta, PHD
Journal: Blood
Blood (2007) 110 (11): 1874.
https://doi.org/10.1182/blood.V110.11.1874.1874
Published: 2007